Biomarker may predict which HER2-negative breast cancer patients will benefit from ta

[News]

A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond - and which should switch to...

More... (http://www.medicalnewstoday.com/releases/299699.php)